Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Agreed
That has been one of my only concerns but with the price of oil rising (until lately) I think it has been offset. It certainly was a great move relocating to Indiana.
Going forward I am very excited to hear projections, plans for the plant in Europe and advancements in the algae products.
NO BPA IN CERP PRODUCTS
With the recent run-up, I am sure we will get a lot of new inquiries about this. Here's an article from last year citing CERP's CEO. For all the newbies, welcome to the party!
February 02, 2010 06:00 AM Eastern Time
Cereplast Applauds the FDA for Demanding Increased Study of BPA
Bioplastics Set to Take Center Stage as Regulatory and Consumer Attitudes Towards Traditional Plastics Turn
HAWTHORNE, Calif.--(BUSINESS WIRE)--Cereplast, Inc. (OTCBB:CERP), manufacturer of proprietary bio-based sustainable plastics, applauds the Food and Drug Administration (FDA) for demanding increased study of the long-term effects of Bisphenol A (BPA) exposure.
“The increased level of safety, coupled with the fact that bioplastics are renewable and eco-friendly means less potential for opposition in regards to their expanded use, especially in applications such as toys, food service ware, infant furniture, etc.”
BPA is a manufacturing chemical employed mainly in the production of clear and hard plastics known as "polycarbonate” and is found in a great number of consumer products including baby bottles and recyclable water bottles. It is also used in epoxy resins, a thermosetting resin, which is used as a protective lining on the inner side of beverage cans and metal-based food tins.
“After a multitude of research, the FDA expressed concern regarding the potential harmful effects of BPA and the increased risks of cancer for humans -- reversing the agency's controversial 2008 ruling,” said Frederic Scheer, Founder, Chairman and CEO of Cereplast, Inc.
After the repeated urging of consumer and watchdog groups at the end of the past decade, the FDA, which initially approved the use of BPA as a food contact subject or indirect food additive in the late 1960s, began reinvestigating the chemical’s use in products that come in contact with food. As part of its recent statement, the FDA called for additional BPA studies by both government and non-government organizations and also announced a set of studies by its own National Center for Toxicological Research focusing on the safety of low doses of BPA.
“While even the most recent studies documenting the effects of BPA on humans are largely inconclusive and the FDA has made no moves of yet to ban the substance in plastics, bioplastics provide the safe alternative. Bioplastics firms like Cereplast are offering BPA-free alternatives and finding ourselves in greater favor among consumers and manufacturers,” said Scheer. “The increased level of safety, coupled with the fact that bioplastics are renewable and eco-friendly means less potential for opposition in regards to their expanded use, especially in applications such as toys, food service ware, infant furniture, etc.”
In the interim, the U.S. Department of Health and Human Services has released recommended ways for the public to reduce their exposure to BPA at http://www.hhs.gov/safety/bpa.
Cereplast offers two families of resins: Cereplast Compostables® are renewable, ecologically sound substitutes for petroleum-based plastic products that replace nearly 100% of the petroleum-based additives used in traditional plastics with bio-based material such as corn, wheat, tapioca and potato starches. Cereplast Compostables® are a proprietary and patented formulation from Cereplast using Ingeo® biopolymers from NatureWorks. Cereplast Hybrids® are resins consisting of traditional polyolefins with up-to 50% renewable content. Cereplast recently announced the launch of an Algae Plastic that will substitute agricultural feedstock with algae as soon as 2011.
About Cereplast, Inc.
Cereplast, Inc. (OTCBB:CERP) designs and manufactures proprietary bio-based, sustainable plastics which are used as substitutes for petroleum-based plastics in all major converting processes - such as injection molding, thermoforming, blow molding and extrusions - at a pricing structure that is competitive with petroleum-based plastics. On the cutting-edge of bio-based plastic material development, Cereplast now offers resins to meet a variety of customer demands. Cereplast Compostables® Resins are ideally suited for single use applications where high bio-based content and compostability are advantageous, especially in the food service industry. Cereplast Hybrid Resins® combine high bio-based content with the durability and endurance of traditional plastic, making them ideal for applications in industries such as automotive, consumer electronics and packaging. Learn more at www.cereplast.com
Safe Harbor Statement
Matters discussed in this press release contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. When used in this press release, the words "anticipate," "believe," "estimate," "may," "intend," "expect" and similar expressions identify such forward-looking statements. Actual results, performance or achievements could differ materially from those contemplated, expressed or implied by the forward-looking statements contained herein. These forward-looking statements are based largely on the expectations of the Company and are subject to a number of risks and uncertainties. These include, but are not limited to, risks and uncertainties associated with: the impact of economic, competitive and other factors affecting the Company and its operations, markets, product, and distributor performance, the impact on the national and local economies resulting from terrorist actions, and U.S. actions subsequently; and other factors detailed in reports filed by the Company.
Anyone else hear that whisper? "Close over 5...close over 5."
CERP is going to pop up on the radar screens of larger firms soon. If earnings meet company projections us little guys will get a huge boost from the institutions...especially if it moves over 5.
My thoughts exactly.
I was wondering who Nat-ur was. I scanned the Nov 10q and there is no mention of a subsidiary. The El Sagundo location certainly connects the dots, but I'm interested to understand the full relationship and how the product is sold and distributed.
Nice.
MiMedx Receives Grant for Its CollaFix Drug Delivery Device
Fantastic news today! We know these products hinge on FDA Approval, but MDXG continues to show the more and more potential for their products. Antibiotics are routinely added to cement when used in joint replacement surgery for prophylactic reasons. Infections are one of the biggest concerns for a surgeons, hospitals and patients. If approved, and clinical data supports the benefit of using a product like this, it could be a game changer for the industry.
It has been a little too long for some good PR from MDXG. Hopefully this is just the start!
Just a note, I am neither a surgeon nor a financial advisor. This is just my opinion.
Nice hire. The SOLO connection is fantastic!
With ~2.5 mil through 3 quarters, they are projecting 5.5-7.5 mil for Q4 to meet their 8-10 mil 2010 projection. It isn't in the bag by any means, but that rate seems possible, all be it aggressive. If they make it happen, us longs will be very pleased.
Can you elaborate or post a link, please.
Thanks.
It is not approved. Read the article from a few posts back. It sounds like at best it will need another study which will further delay the approval. GLTA.
Well, somebody is taking notice! According to Yahoo!, the after hours trade at 7:52 was $3.89--almost a 19% jump. We will see if this holds in the am.
I like how it isn't closely followed (yet) but has a great plan and has executed extremely well to this point. The only concerns are the European financial issues (which were slightly relieved today and may be countered by legislation to eliminate use of plastic bags in several countries) and the price of corn (any commodity-dependent stock needs to take this into consideration, especially now). That being said, I'm good here! I am excited about the potential here and I am in for the long haul if we continue on this tract.
All my humblle opinion. Be sure to make your own decisions and always protect your unit!
Been looking for news of any kind but can't seem to find any. Earnings don't come out for a couple weeks, as far as I know. Any thoughts or insight?
I for one am quite confident in their projections. The relocation and opening of their plant in Indiana will help with margins an they continue to add contracts. Although a lot of their contracts won't be reaching full potential until Q1 2011, I believe they have enough business to meet their goals for EOY. Execution, as we know, is key. I feel the management has shown they can execute to this point and I haven't seen any red flags that would make change my mind.
Anyone have any insight into the quick drop in pps over the past week, especially the big drop this morning? Is it just going with the market this week? Buy op?
That's approximately 2.6-3.9 million lbs/year. CERP is on track to ship 16 million lbs for 2010! Looks like a great start for 2011 growth!
He's certainly not as popular as Dr. Sanjay Gupta, but he is always on NBC talking about advances in medical technology. Definitely a positive.
cngreen, you are exactly right. The sole purpose of a drug rep is to educate doctors/PAs and to increase visibility and use of their products. Here in Florida, there is a sweeping movement to get away from addictive pain meds. (For example, I posted an article about a month ago about crack-downs on pain clinics)
Nyloxin isn't a cure all...nothing is...but I'm willing to bet doctors will rx it.
Well said. EOM.
Great pub. The share price reacted to the news yesterday along with the enhanced exposure with the NASDAQ ringing and the interview on CNBC. Scheer is doing a great job, IMHO. He knows the industry and will be on the cutting edge of the industry as the founder of the Biodegradable Products Institute.
Thanks for all your work, Raw.
Larry Oakley has a better CV than a lot of people on this board. He may be small change in your view, but he does garner some respect: http://www.wallstreetcorner.com/lco-cs.doc
Congrats to SOMX. That is a great opportunity for them. I'm sure we all wish we had a stake in that before today. However, your comparison of PG and XCHO/Cobroxin is apples and rutabagas. SOMX is a small (not micro) cap stock with an FDA approved drug, not a nutraceutical. We all know the Jets could beat Hoover High, why try to initiate an arguement?
I will be watching tomorrow. They are interviewing Wendy Williams on cnbc after she rings the NASDAQ today so I hope we get the same.
Great news. Now if they can get some more US companies on board, this thing would explode. For now i am very pleased with their international growth.
Also, has anyone noticed how this is holding up as the rest of the market slides. Of course, they had a tough ride earlier in the year. This could be a great opportunity to accumulate.
That's a CEO who is doing all he can to get the word out on both the product/industry and his company. Hopefully they get a good follow-up interview on CNBC and other financial networks after they ring the bell on Thursday! I'll be watching.
This was the text for the RiteAid weekly circular (page 10)
Cobroxin for Chronic Pain Gel 2 oz.
price with wellness+ card
Price: $14.99
(After $1.00 +up reward, it's like paying $13.99!)
Valid Until:08/28/2010
Thanks...and thanks.
Your opinion has been heard and appreciated. If there is anyone on this board that doesn't know your opinion based on your interpretation of the facts they should have their head examined. It is always good to have balance on any board, however, IMHO, you have become an overwhelming presence by refuting ANYONE'S positive comments. For example, after repeatedly blasting XCHO for lack of commercials, you then state it may not be a good thing based on when and where the add is placed. While your comment has some merit, it's a little overkill at this point.
The bottom line is, we see your point of view. As investors, we are all individually responsible for the choices we make. Thank you for bringing an opposing point of view to lend balance to our decision making process. Hopefully, if the time comes, you can point out a positive for XCHO.
Rawnoc,
Thanks for all you work and finding these articles. In this one, when they refer to cereplast do they mean the CERP product? I only ask since it's not capitalized but I am not aware of this term already being used like Kleenex.
Thanks.
Agreed.
I don't appreciate you saying I am biased. I am not. You deal in facts and your opinion on me is just that. Here's a fact: all drugs are "promising" until they are found to have problems. Check these facts on drug approval:
http://www.fda.gov/drugs/resourcesforyou/consumers/ucm143534.htm
And...
"The FDA is being more cautious," analyst Steve Brozak of WBB Securities said, explaining that FDA staff now realize new drugs will be used by many patients beyond those intended — known as off-label use because the drug is taken for another condition than the one it was approved to treat. That often boosts the chances that some patients will be harmed by side effects.
He sees the FDA mentality now as: "It's got to be so safe that we're not going to be criticized ever" for approving a drug.
The agency has approved 61 percent of drug applications through mid-August, down from 73 percent in the same period last year, according to BioMedTracker, a biotech and pharmaceutical research service.
Already, the average process of shepherding a potential drug from discovery through approval takes 14.2 years, according to Tufts.
Some patients and their families say that can be too long. Frank Burroughs' daughter, Abigail, was denied access to experimental cancer drugs and died in 2001. The drug she was seeking was later approved. He went on to found an organization that sued the FDA in 2003 seeking access to experimental drugs for terminally ill people. Earlier this month, the court ruled that dying patients don't don't have the constitutional right to potentially lifesaving drugs that haven't been approved yet by the FDA.
“Terminally ill patients desperately need curative treatments,” Judge Thomas B. Griffith wrote for the majority. But “their deaths can certainly be hastened by the use of a potentially toxic drug with no proven therapeutic benefit.”
James Kumpel at Friedman, Billings, Ramsey & Co. just published a report showing FDA approvals of "new molecular entities" — drugs made from new chemical compounds rather then just twists on existing drugs — so far this year are at their lowest level in at least a decade. Only seven were approved through the end of July, versus an average of 12 over the first seven months of each year since 1998.
"The FDA certainly has made it more difficult for pharmaceutical companies by pushing for more data and for more participants and for longer studies," said Kumpel, barriers he said will start limiting the number of new blockbusters.
"It appears that FDA has been on defense since 2004," Kumpel said.
Don't blame xcho. They have paid for their inventory, although we all wish xcho would have to buy more stock. Nphc spends a ton on R+D. That's where their cash goes.
Intersting that CERP was not cited, especially since some of the things CERP is working on (algea not food-based) technologies will be needed. They also just opened their state of the art plant, which they think will be at max production in 2 years. Seems they would have been interviewed but all in all a great article for the sector.
Don't get your hopes upon any pipeline drugs. I know you have enough experience to realize there is a high probability none will come to market an even if they do, they are years away. Of course they could stop making Cobroxin, but as their only current revenue source that may be foolish. It will be interesting to see how much Nyloxin is sold in Q3 to HS and the foreign distributors. Hopefully they blow it out! That would be best for all parties and may drop Rik's stress level a little so he releases slightly more professional pr's.
Great job. Your observations are clear and a lot of what I use when making my initial investments in both these companies...I have 5x as much XCHO compared to NPHC...with a lot based on the cost of marketing v. R+D. Also, revenues were obviously going to be substantially higher for XCHO. If individuals don't know how supplier/distributor revenues are different, they should stay out of this sector.
At this point, the jury is still out on both of these. We absolutely must have the marketing work. If that occurs, sales will increase and all will be happy. If not, the only product XCHO has that is generating revenue will be lost and NPHC will fall victim to most start-up biotechs and run out of cash. It's not over yet by any means but must be watched closely.
JMHO
Agreed.
It's the $6 million that's a concern. They did a $7.5 million offering in June and I know they said they think that is the last they will need before profitability. I would just like to see a little more cushion. Of course, that's why they have a CFO, and that I am not.